Dr. Kraveka is graduate of Columbia University. She obtained her medical degree from Nova Southeastern University in North Miami Beach, Florida, in 1994. She completed her pediatric residency at Miami Children’s Hospital and her fellowship in Pediatric Hematology-Oncology at the Medical University of South Carolina. Dr. Kraveka is actively involved in clinical pediatric research in the Children’s Oncology Group, where she is a member of the Non-Hodgkin’s Lymphoma and Neuroblastoma Committees. As the institutional COG Principal Investigator, she is responsible for the conduct of over 40 COG Phase II and Phase III trials at MUSC. Dr. Kraveka has served as the study chair for the COG Study, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen. In addition, she also serves as the institutional Principal Investigator for the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). NMTRC consists of a group of closely collaborating investigators who are linked with laboratory programs to develop novel therapies. Those treatments with promising results will then be considered for more extensive national testing. In addition to clinical research, she is also very involved in translational and bench research and has the only research laboratory in South Carolina dedicated to pediatric cancer. Her current research focuses on sphingolipid mediated signal transduction in pediatric cancers, the function and regulation of the enzyme dihydroceramide desaturase in human cancer and the regulation of MYCN oncogene by sphingolipids. The long-term goal of her research is to develop novel therapeutic strategies for the treatment of childhood cancer.